Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Revenue of Sol-Gel Technologies Ltd. (SLGL)
Revenue in 2023 (TTM): $1.55 M
According to Sol-Gel Technologies Ltd.'s latest financial reports the company's current revenue (TTM) is $1.55 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Sol-Gel Technologies Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.55 M | $-21,987,000 | $-28,963,000 | $-27,238,000 | $-27,238,000 |
| 2022 | $3.88 M | $-8,799,000 | $-15,682,000 | $-14,923,000 | $-13,602,000 |
| 2021 | $31.27 M | $10.89 M | $3.84 M | $3.22 M | $4.36 M |
| 2020 | $8.77 M | $-19,142,000 | $-29,287,000 | $-29,290,000 | $-27,401,000 |
| 2019 | $22.9 M | $-17,674,000 | $-25,063,000 | $-24,576,000 | $-24,609,000 |
| 2018 | $129 K | $-28,017,000 | $-32,759,000 | $-32,203,000 | $-32,203,000 |
| 2017 | $174 K | $-126,000 | $-31,162,000 | $-31,568,000 | $-31,568,000 |
| 2016 | $ | $-359,000 | $-20,397,000 | $-20,771,000 | $-20,771,000 |
| 2015 | $ | $-300,000 | $-9,347,000 | $-9,660,000 | $-9,660,000 |
| 2014 | $ | $ | $-4,583,000 | $-4,848,000 | $-4,848,000 |